ReviewCellular oncology (Dordrecht, Netherlands)2012
Aberrant microRNA expression and its implications in the pathogenesis of leukemias.
Review in Cellular oncology (Dordrecht, Netherlands), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 74 citations in OpenAlex.
- miR-193a-5p-mediated Inhibition of the METTL1/COX-2 axis is critical for Astragalin-induced apoptosis in cervical cancer.Scientific reports · 2025Article
- Article
- Article
- Upregulation of lnc-FOXD2-AS1, CDC45, and CDK1 in patients with primary non-M3 AML is associated with a worse prognosis.Blood research · 2024Article
- Exosomes derived from colorectal cancer cells take part in activation of stromal fibroblasts through regulating PHLPP isoforms.EXCLI journal · 2024Article
- The Promising Role of Non-Coding RNAs as Biomarkers and Therapeutic Targets for Leukemia.Genes · 2023Review
- Global research trends in extracellular vesicles based on stem cells from 1991 to 2021: A bibliometric and visualized study.Frontiers in bioengineering and biotechnology · 2022Article
- Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma.Journal of cellular and molecular medicine · 2022Review
- Up-regulation of miR-155 potentiates CD34+ CML stem/progenitor cells to escape from the growth-inhibitory effects of TGF-ß1 and BMP signaling.EXCLI journal · 2021Article
- Non-coding RNAs underlying chemoresistance in gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2020Review
- Aberrant expression of a five-microRNA signature in breast carcinoma as a promising biomarker for diagnosis.Journal of clinical laboratory analysis · 2020Article
- LeukmiR: a database for miRNAs and their targets in acute lymphoblastic leukemia.Database : the journal of biological databases and curation · 2020Article
- Gestational Diabetes Mellitus Regulatory Network Identifies hsa-miR-145-5p and hsa-miR-875-5p as Potential Biomarkers.International journal of endocrinology and metabolism · 2019Article
- Exome, transcriptome and miRNA analysis don't reveal any molecular markers of TKI efficacy in primary CML patients.BMC medical genomics · 2019Article
- miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis.International journal of biological sciences · 2019Article
- miR-9 upregulation leads to inhibition of erythropoiesis by repressing FoxO3.Scientific reports · 2018Article
- Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.Leukemia · 2017Article
- Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.Cellular oncology (Dordrecht, Netherlands) · 2016Review
- Increased Levels of miRNA-146a in Serum and Histologic Samples of Patients with Uveal Melanoma.Frontiers in pharmacology · 2016Article
- Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.Diagnostic pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) are a class of non-coding, endogenous, small RNAs that negatively regulate gene expression by inducing degradation or translational inhibition of target mRNAs. Aberrant expression of miRNAs appears to be a common characteristic of hematological malignancies including leukemias.
aimHere we review the available data supporting a role of aberrant expression of miRNAs in the pathogenesis of leukemias including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL).
conclusionsThe expression signatures of miRNAs provide exciting opportunities in the diagnosis, prognosis, and therapy of leukemia. Since miRNAs can function as either oncogenes or tumor suppressor genes in leukemogenesis, the potential of using these small RNAs as therapeutic targets opens up new opportunities for leukemia therapy by either inhibiting or augmenting their activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.